Company Description

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease.

The company was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme

Country	France
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	67
CEO	Marc M. de Garidel

Contact Details

Address: 7-11 boulevard Haussmann Paris, 75009 France
Phone	33 1 53 83 09 63
Website	abivax.com

Stock Details

Ticker Symbol	ABVX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	EUR
IPO Price	$11.60
CIK Code	1956827
CUSIP Number	00370M103
ISIN Number	US00370M1036
SIC Code	2834

Key Executives

Name	Position
Marc M. P. de Garidel M.B.A.	Chief Executive Officer
Didier Blondel	EVice President, Chief Financial Officer and Board Secretary

Latest SEC Filings

Date	Type	Title
Mar 23, 2026	S-8	Securities to be offered to employees in employee benefit plans
Mar 23, 2026	20-F	Annual and transition report of foreign private issuers
Mar 23, 2026	6-K	Report of foreign issuer
Feb 23, 2026	6-K	Report of foreign issuer
Feb 13, 2026	SCHEDULE 13G/A	Filing
Jan 14, 2026	SCHEDULE 13D/A	Filing
Jan 8, 2026	144	Filing
Dec 15, 2025	6-K	Report of foreign issuer
Nov 14, 2025	SCHEDULE 13G/A	Filing
Nov 14, 2025	SCHEDULE 13G/A	Filing

View All SEC Filings